Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma - Takeaways - MDSpire

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

  • By

  • Eric Jurgens

  • Tala Shekarkhand

  • Colin Rueda

  • David Nemirovsky

  • Andriy Derkach

  • Ross S. Firestone

  • Kevin Miller

  • Bruno Almeida Costa

  • Sridevi Rajeeve

  • Alexander M. Lesokhin

  • Neha Korde

  • Carlyn R. Tan

  • Hamza Hashmi

  • Hani Hassoun

  • Kylee Maclachlan

  • Urvi A. Shah

  • Malin Hultcrantz

  • Issam Hamadeh

  • Sergio A. Giralt

  • Gunjan L. Shah

  • Heather J. Landau

  • Michael Scordo

  • Saad Z. Usmani

  • Sham Mailankody

  • Zainab Shahid

  • November 1, 2025

  • 0 min

Share

  • 1

    Bispecific antibodies (BsAbs) show significant efficacy in treating relapsed/refractory multiple myeloma, but infectious complications are common.

  • 2

    Cytomegalovirus (CMV) reactivation occurs in 8% of patients receiving BsAbs, with some studies reporting rates as high as 49%.

  • 3

    In a study of 85 CMV seropositive patients, the cumulative incidence of CMV reactivation was 36% by Day 180 of BsAb therapy.

  • 4

    Four patients developed clinically significant CMV infections, with treatment initiated a median of 85.5 days after starting BsAb therapy.

  • 5

    Steroid treatment for cytokine release syndrome increased the risk of CMV detection, but baseline characteristics did not predict CMV reactivation.

Original Source(s)

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

  • by Eric Jurgens, Tala Shekarkhand, Colin Rueda, David Nemirovsky, Andriy Derkach, Ross S. Firestone, Kevin Miller, Bruno Almeida Costa, Sridevi Rajeeve, Alexander M. Lesokhin, Neha Korde, Carlyn R. Tan, Hamza Hashmi, Hani Hassoun, Kylee Maclachlan, Urvi A. Shah, Malin Hultcrantz, Issam Hamadeh, Sergio A. Giralt, Gunjan L. Shah, Heather J. Landau, Michael Scordo, Saad Z. Usmani, Sham Mailankody, Zainab Shahid

  • November 1, 2025

Related Content

Evaluating Hypoalbuminemia as a Prognostic Indicator in Monoclonal Gammopathy of Undetermined Significance (MGUS) within Its Biological Framework

Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min